Thomas Walz - XSpray Pharma Chief Officer

XSPRAY Stock

SEK 41.40 1.10 2.59%

Insider

Thomas Walz is Chief Officer of XSpray Pharma AB

Age	63
Phone	46 87 30 37 00
Web	https://www.xspraypharma.com

XSpray Pharma Management Efficiency

The company has return on total asset (ROA) of (0.1448) % which means that it has lost $0.1448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2423) %, meaning that it generated substantial loss on money invested by shareholders. XSpray Pharma's management efficiency ratios could be used to measure how well XSpray Pharma manages its routine affairs as well as how well it operates its assets and liabilities.

Compare XSpray Pharma to Peers

Predict price of XSpray Pharma

XSpray Pharma AB has accumulated 1.19 M in total debt with debt to equity ratio (D/E) of 2.8, implying the company greatly relies on financing operations through barrowing. XSpray Pharma AB has a current ratio of 25.92, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist XSpray Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, XSpray Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like XSpray Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for XSpray to invest in growth at high rates of return. When we think about XSpray Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Johan Raud	Vicore Pharma Holding	N/A
	Johanna Christensen	Cantargia AB	N/A
	Christer Mller	BioArctic AB	64
	Samuel Wagner	Xbrane Biopharma AB	N/A
	Thoas MD	Cantargia AB	61
	Dominique Tersago	Cantargia AB	61
	Katja Margell	Hansa Biopharma AB	N/A
	Klaus Sindahl	Hansa Biopharma AB	N/A
	Adnan Deronic	Cantargia AB	N/A
	Harald Borgeke	BioArctic AB	N/A
	Marcuss	Cantargia AB	N/A
	Erik Domines	Xbrane Biopharma AB	59
	Hans Jeppsson	Vicore Pharma Holding	N/A
	Maria Edebrink	Xbrane Biopharma AB	54
	David Vikstrm	Xbrane Biopharma AB	46
	Nina Valkama	Cantargia AB	N/A
	Elin Rosendahl	Vicore Pharma Holding	N/A
	Emanuel Bjrne	Hansa Biopharma AB	50
	Sren MSc	Hansa Biopharma AB	58
	Frida Lekander	BioArctic AB	N/A
	Associate Gier	Xbrane Biopharma AB	N/A

Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden. XSpray Pharma AB (XSPRAY) is traded on Stockholm Exchange in Sweden and employs 26 people.

Management Performance

	Return On Equity	-0.24
	Return On Asset	-0.14

XSpray Pharma AB Leadership Team

Elected by the shareholders, the XSpray Pharma's board of directors comprises two types of representatives: XSpray Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XSpray. The board's role is to monitor XSpray Pharma's management team and ensure that shareholders' interests are well served. XSpray Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XSpray Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Kerstin Hasselgren, Chief Officer
	Per Andersson, Chief Officer
	Charlotta Liljebris, VP RD
	Andreas Konar, Sr Devel
	Thomas Walz, Chief Officer
	AnnaKarin Ekberg, VP Sales
	Christina Hagerstrand, VP Relations
	Grald Jesson, VP Operations
	Mustafa Demirbker, CoFounder Director

XSpray Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XSpray Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.24
	Return On Asset	-0.14
	Operating Margin	(116.51) %
	Current Valuation	1.16 B
	Shares Outstanding	22.68 M
	Shares Owned By Insiders	47.42 %
	Shares Owned By Institutions	27.60 %
	Price To Book	2.35 X
	Price To Sales	1,206 X
	Gross Profit	656 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Other Information on Investing in XSpray Stock

XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC